Eur Respir J:脓毒症患者的生存率与外周血白细胞端粒长度有关

2019-10-21 xing.T MedSci原创

在危重病患者,特别是脓毒症患者中,较短的PBL-TL与较差的生存率和更严重的ARDS密切相关。这些结果表明端粒功能障碍可能导致危重病患者较差的预后。

在各种慢性肺病中,较短的外周血白细胞(PBL)端粒长度(TL)与不良预后有关。近日,呼吸疾病领域权威杂志Eur Respir J上发表了一篇研究文章,这项研究旨在明确PBL-TL是否与危重病患者生存率有关。

研究人员分析了范德比尔特大学医学中心(VUMC)对937名危重患者进行的前瞻性观察性队列研究的数据。通过qPCR测量从PBL分离的DNA的TL。这一结果在加利福尼亚大学旧金山分校(UCSF)招募的394名重症脓毒症患者组成的独立队列进行了验证。

在VUMC队列中,较短的PBL-TL与较差的90天生存率相关( TL每减少1kb调整后的HR为1.3,95%CI为[1.1-1.6],p=0.004);在亚组分析中,脓毒症患者较短的PBL-TL与较差的90天生存率相关( TL每减少1kb调整后的HR为1.5,95%CI为[1.2-2.0],p=0.001),但在创伤患者中无关。尽管与ARDS的发展无关,但在ARDS受试者中,较短的PBL-TL与更严重的ARDS有关(TL每减少1kb的OR为1.7,95%CI为[1.2–2.5],p=0.006)。PBL-TL与生存率(TL每减少1kb调整后的HR为1.6,95%CI为[1.2-2.1],p=0.003)和发生严重ARDS风险(TL每减少1kb的OR为2.5,95%CI为[ [1.1–6.3],p=0.044)之间的相关性在UCSF队列中得到了验证。

在危重病患者,特别是脓毒症患者中,较短的PBL-TL与较差的生存率和更严重的ARDS密切相关。这些结果表明端粒功能障碍可能导致危重病患者较差的预后。 

原始出处:

Shuo Liu,et al.Peripheral Blood Leukocyte Telomere Length is Associated with Survival of Sepsis Patients.Eur Respir J.2019.https://erj.ersjournals.com/content/early/2019/09/25/13993003.01044-2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1256729, encodeId=60ca1256e29e6, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Oct 23 09:44:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288643, encodeId=24bd128864341, content=<a href='/topic/show?id=8d20e5696c5' target=_blank style='color:#2F92EE;'>#端粒长度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75696, encryptionId=8d20e5696c5, topicName=端粒长度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Oct 23 09:44:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516379, encodeId=22d515163e9ca, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Wed Oct 23 09:44:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578557, encodeId=065015e8557d6, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Wed Oct 23 09:44:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1256729, encodeId=60ca1256e29e6, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Oct 23 09:44:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288643, encodeId=24bd128864341, content=<a href='/topic/show?id=8d20e5696c5' target=_blank style='color:#2F92EE;'>#端粒长度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75696, encryptionId=8d20e5696c5, topicName=端粒长度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Oct 23 09:44:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516379, encodeId=22d515163e9ca, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Wed Oct 23 09:44:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578557, encodeId=065015e8557d6, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Wed Oct 23 09:44:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1256729, encodeId=60ca1256e29e6, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Oct 23 09:44:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288643, encodeId=24bd128864341, content=<a href='/topic/show?id=8d20e5696c5' target=_blank style='color:#2F92EE;'>#端粒长度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75696, encryptionId=8d20e5696c5, topicName=端粒长度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Oct 23 09:44:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516379, encodeId=22d515163e9ca, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Wed Oct 23 09:44:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578557, encodeId=065015e8557d6, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Wed Oct 23 09:44:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1256729, encodeId=60ca1256e29e6, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Oct 23 09:44:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288643, encodeId=24bd128864341, content=<a href='/topic/show?id=8d20e5696c5' target=_blank style='color:#2F92EE;'>#端粒长度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75696, encryptionId=8d20e5696c5, topicName=端粒长度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Oct 23 09:44:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516379, encodeId=22d515163e9ca, content=<a href='/topic/show?id=a5598519866' target=_blank style='color:#2F92EE;'>#脓毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85198, encryptionId=a5598519866, topicName=脓毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7310955580, createdName=dlwang_26703130, createdTime=Wed Oct 23 09:44:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578557, encodeId=065015e8557d6, content=<a href='/topic/show?id=fd724282021' target=_blank style='color:#2F92EE;'>#外周血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42820, encryptionId=fd724282021, topicName=外周血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31916414168, createdName=ms3994565386320060, createdTime=Wed Oct 23 09:44:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]

相关资讯

Blood:脓毒症时,血小板的转录本和翻译组均发生明显改变

越来越多的人认识到血小板在脓毒症的病理生理过程中具有重要的作用,但这一点目前还没有明确的定义。脓毒症是否会改变人类血小板的转录和翻译尚未明确。近日,《Blood》杂志上发表一篇文章,研究人员利用RNA测序和核糖体足迹分析来研究脓毒症患者和健康献血者的血小板的转录组和翻译组。研究人员从脓毒症患者的血小板中共鉴定出1806个表达具有显著差异的转录本(FDR < 0.05)。在脓毒症过程中,血小板

Crit Care Med:脓毒症与微血管脑损伤的关系

由此可见,通过微血管梗塞评估,脓毒症与中度至重度血管脑损伤特异性相关。对于大脑皮质内的微小梗塞,这种关联更强,那些经历严重脓毒症住院治疗的患者在调整分析中有中度至重度大脑皮质损伤证据的可能性超过两倍。需要进一步研究以确定脓毒症和微小梗塞之间的相关机制。

Clinica Chimica Acta:采用新型LC-MS/MS法测定脓毒症休克时血浆缓激肽浓度

缓激肽是炎症和血管通透性的重要介质,在感染性休克的发生过程中可能发挥重要作用。然而,采用免疫学方法测定缓激肽可能受到干扰,且缺乏特异性。因此本研究建立了血浆缓激肽的液相色谱 · 2019-08-06

-->

Crit Care:发病前β受体阻滞剂暴露与脓毒症死亡率之间的关联

由此可见,该系统评价表明败血症发病前的β受体阻滞剂暴露与死亡率降低有关。没有足够的数据进行真正的荟萃分析,目前尚不清楚死亡率的明显降低是否可归因于过量儿茶酚胺的减少。

Crit Care:造影剂对脓毒症相关的急性肾损伤患者肾功能和预后影响

由此可见,单次给予造影剂与脓毒症患者AKI恶化或短期/长期死亡率增加无关。

美国FDA授予Nangibotide治疗感染性休克的快速通道资格

Inotrem是一家专门从事慢性炎症综合征免疫治疗的生物技术公司,近日宣布美国FDA已授予Nangibotide快速通道资格,用于治疗感染性休克。Nangibotide是一种TREM-1抑制剂肽,能够恢复适当的炎症反应,并改善血管功能和脓毒症后的存活。